SURUNKALI KASALLIGI BOR BEMORLARDA NOSTEROID YALLIG‘LANISHGA QARSHI DORILARNI UZOQ MUDDAT QO‘LLASHNING OSHQOZON-ICHAK ASORATLARIGA TA’SIRI
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstrak:
Nonsteroid yallig‘lanishga qarshi dorilar (NYSKD) surunkali kasalliklar, xususan revmatoid artrit, osteoartrit, surunkali bel og‘rig‘i va boshqa yallig‘lanish kasalliklari bilan og‘rigan bemorlarda keng qo‘llaniladi. Uzoq muddatli davolash samaradorligini oshirishi bilan birga oshqozon-ichak traktiga jiddiy asoratlar keltirib chiqarishi mumkin. Mazkur maqolada NYSKD’ning farmakologik xususiyatlari, uzoq muddat qo‘llash natijasida oshqozon va ichak mukozasida yuzaga keladigan erosiyalar, yaralar, dispeptik simptomlar va gastrointestinal qon ketish xavfi batafsil tahlil qilinadi. Shu bilan birga, bemorlarni xavf guruhiga ajratish, profilaktik choralar (masalan, proton nasos inhibitorlari va misoprostol qo‘llash) va monitoring strategiyalari ko‘rib chiqiladi. Tadqiqotlar shuni ko‘rsatadiki, NYSKD’ni uzoq muddat qo‘llashda individual risk faktorlari – bemorning yoshi, surunkali kasallik turi, dori dozasi va qo‘shma terapevtik preparatlar bilan davolanish – oshqozon-ichak asoratlari ehtimolini sezilarli darajada oshiradi. Maqolada, shuningdek, klinik amaliyotda NYSKD’ni xavfsiz va samarali qo‘llash bo‘yicha tavsiyalar taqdim etiladi.
##plugins.themes.bootstrap3.article.details##
##submission.howToCite##:
##submission.citations##:
Laine, L. (2001). Approaches to nonsteroidal anti-inflammatory drug use in high-risk patients. Gastroenterology, 120(3), 594–606.
Bjarnason, I., et al. (2018). Gastrointestinal safety of NSAIDs: Clinical guidelines and evidence. Alimentary Pharmacology & Therapeutics, 47(3), 281–296.
Sostres, C., & Lanas, A. (2011). Gastrointestinal risks of NSAIDs: A clinical perspective. Drugs, 71(8), 1151–1169.
Moore, N., et al. (2015). NSAIDs and gastrointestinal complications: Epidemiology and prevention. Therapeutics and Clinical Risk Management, 11, 1427–1438.
Chan, F. K., et al. (2007). Gastroprotective strategies for NSAID users. New England Journal of Medicine, 357(21), 2102–2110.
Wallace, J. L. (2012). Prostaglandins and gastrointestinal mucosal defense. Clinical Gastroenterology and Hepatology, 10(10), 1143–1153.
Hunt, R. H., & Fordtran, J. S. (2010). Textbook of Gastroenterology, 5th Edition. Philadelphia: Saunders, pp. 2050–2068.
Wolfe, M. M., Lichtenstein, D. R., & Singh, G. (1999). Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. New England Journal of Medicine, 340(24), 1888–1899.
Lanas, A., et al. (2013). Nonsteroidal anti-inflammatory drugs and gastrointestinal complications: An update. Digestive and Liver Disease, 45(5), 342–349.
Tursunov, R., & Abdullayev, M. (2017). Nonsteroid yallig‘lanishga qarshi dorilarning oshqozon-ichak asoratlari va ularni oldini olish usullari. Tibbiyot olami, 6(2), 45–52.
Laine, L., & Takeuchi, K. (2009). COX-2 selective inhibitors and the gastrointestinal tract. Alimentary Pharmacology & Therapeutics, 30(5), 393–408.
Moiseev, S. V., et al. (2014). Long-term NSAID therapy in patients with rheumatic diseases: Gastrointestinal risks and prevention. Rheumatology International, 34(7), 947–956.
Karimov, B. (2020). Surunkali revmatik kasalliklarda NYSKD terapiyasining xavfsizligi va samaradorligi. O‘zbekistonda Sog‘liqni Saqlash Ilmiy Jurnali, 4(1), 12–20.
Lanas, A., & Scheiman, J. (2007). Low-dose aspirin and NSAID-related gastrointestinal complications. American Journal of Gastroenterology, 102(3), 228–234.
McCarthy, G. M., & Bombardier, C. (2006). Gastrointestinal safety in long-term NSAID users: Evidence-based review. Arthritis & Rheumatism, 54(9), 2761–2772.